Home/ Stocks/ AVIR

Atea Pharmaceuticals, Inc. Common Stock

AVIR XNAS

$5.25 +0.36 (+7.21%) ▲ 15-min delayed

Open

$4.97

High

$5.30

Low

$4.97

Volume

265.0K

Market Cap

$399.34M

About Atea Pharmaceuticals, Inc. Common Stock

Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 55 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-45,440,000	$-0.57
FY 2025	$0	$-158,349,000	$-1.94
Q3 2025	$0	$-42,049,000	$-0.53
Q2 2025	$0	$-37,161,000	$-0.44

Related Market News

No specific coverage for AVIR yet. Check out our latest market news or earnings calendar.

Get AVIR Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Atea Pharmaceuticals, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.